Clinuvel Pharmaceuticals (CUV: $9.85) has announced that its CEO, Philippe Wolgen will remain in the role following a search for his replacement. Wolgen was due to step down at the end of June this year.
The next two to three years will be a defining period for the next stage of the company's evolution. Having built a successful biotech business from the development of Scenesse for the treatment of EPP – company revenue of $105 million and net profit of $36 million in FY2025 – Clinuvel is in the midst of a major expansion with the investment in the development of new products and new product applications.
The first of these, Neuracthel, is expected to be filed for approval in Europe this year. It is a specialty generic of ACTH. There are two main ACTH products on the market – Cortropin Gel and Acthar Gel. Cortropin Gel generated net sales of US$347 million last year, up 75% on the PCP. And Acthar Gel sales are tracking at US$726 million, up 44% over the PCP. However most revenue is generated in the US (93% for Acthar Gel).
The next major milestone for Clinuvel is completion of the first Phase III vitiligo study, to be followed by a second Phase III study. This is also a major market opportunity for the company. The second Phase III study is expected to complete recruitment by the end of 2027. Bioshares expects an NDA filing in 2028, and product approval and launch in the first half of 2029 if all goes well. Clinuvel will use the same specialty treatment centres in the US (120 established) to deliver the vitiligo treatment with Scenesse.
Clinuvel is following a textbook path of forming a sustainable and profitable business from a niche market (in EPP), and then expanding the product opportunity with the same product (into vitiligo), or using its expertise in melanocortins to develop new products (Neuracthel) that will compete in substantially larger markets.
Maintaining the current CEO, who has driven the product development over the last two decades, will be highly beneficial to the company. The executive management team will be expanded, which will include a strengthening of the US base, allowing Wolgen to focus on global strategy and governance.
Clinuvel finished with $233 million in cash last year and is capitalized at $493 million.
Bioshares recommendation: Buy
Disclaimer:
Information contained in this newsletter is not a complete analysis of every material fact respecting any company, industry or security. The opinions and estimates herein expressed represent the current judgement of the publisher and are subject to change. Blake Industry and Market Analysis Pty Ltd (BIMA) and any of their associates, officers or staff may have interests in securities referred to herein (Corporations Law s.849). Details contained herein have been prepared for general circulation and do not have regard to any person’s or company’s investment objectives, financial situation and particular needs. Accordingly, no recipients should rely on any recommendation (whether express or implied) contained in this document without consulting their investment adviser (Corporations Law s.851). The persons involved in or responsible for the preparation and publication of this report believe the information herein is accurate but no warranty of accuracy is given and persons seeking to rely on information provided herein should make their own independent enquiries. Details contained herein have been issued on the basis they are only for the particular person or company to whom they have been provided by Blake Industry and Market Analysis Pty Ltd. The Directors and/or associates declare interests in the following ASX Healthcare and Biotechnology sector securities: Analyst MP: 1AD, ACR, AVR, CGS, CUV, CYC, DXB, IMM, LBT, MX1, OPT, NEU, PAB, PXS,RNO,SOM. These interests can change at any time and are not additional recommendations. Holdings in stocks valued at less than $100 are not disclosed.
